Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 198 entries
View as:

Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03397199 Org: User:
Start: 01/09/18 End: 03/31/21 Due: 03/31/22

Study of CT and MR in the Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04028375 Org: User:
Start: 09/01/19 End: 12/01/23 Due: 12/01/24

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

Phase: N/A Priority: Normal
NCT ID: NCT03735966 Org: User:
Start: 11/20/18 End: 10/20/20 Due: 10/20/21

Treatment of Advanced Gastrointestinal Tumors With Albumin Taxol

Phase: N/A Priority: Normal
NCT ID: NCT03977077 Org: User:
Start: 06/01/19 End: 10/31/20 Due: 10/31/21

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

Phase: N/A Priority: Normal
NCT ID: NCT06160362 Org: User:
Start: 10/31/23 End: 12/31/25 Due: 12/31/26

Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib

Phase: N/A Priority: Normal
NCT ID: NCT06478927 Org: User:
Start: 01/15/24 End: 01/15/27 Due: 01/15/28

Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT05490667 Org: User:
Start: 08/20/22 End: 07/31/24 Due: 07/31/25

Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02621333 Org: User:
Start: 10/31/15 End: 09/30/18 Due: 09/30/19

Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04718038 Org: User:
Start: 07/01/16 End: 09/01/20 Due: 09/01/21

SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03950271 Org: User:
Start: 01/20/20 End: 12/31/26 Due: 12/31/27

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04280822 Org: User:
Start: 04/21/20 End: 03/02/28 Due: 03/02/29

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Phase: N/A Priority: Normal
NCT ID: NCT04681287 Org: User:
Start: 04/23/21 End: 12/30/24 Due: 12/30/25

An Observational Study to Evaluate Lymph Metastases and Prognoses of the Patients With Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03415815 Org: User:
Start: 12/12/17 End: 04/30/18 Due: 04/30/19

Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients

Phase: N/A Priority: Normal
NCT ID: NCT06285149 Org: User:
Start: 03/01/24 End: 06/01/25 Due: 06/01/26

Cryoablation for Advanced Bone and Soft Tissue Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05615545 Org: User:
Start: 03/10/22 End: 10/28/24 Due: 10/28/25

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05398861 Org: User:
Start: 06/01/22 End: 12/30/24 Due: 12/30/25

Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Using CT and Multimodal MRI

Phase: N/A Priority: Normal
NCT ID: NCT06833775 Org: User:
Start: 03/31/25 End: 12/31/30 Due: 12/31/31

Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia

Phase: N/A Priority: Normal
NCT ID: NCT06793228 Org: User:
Start: 01/15/25 End: 12/15/27 Due: 12/15/28

A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04615312 Org: User:
Start: 11/14/20 End: 08/30/22 Due: 08/30/23

A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03735511 Org: User:
Start: 11/20/18 End: 08/31/20 Due: 08/31/21

Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06955390 Org: User:
Start: 05/01/25 End: 12/01/26 Due: 12/01/27

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05177068 Org: User:
Start: 05/06/22 End: 01/31/25 Due: 01/31/26

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06329973 Org: User:
Start: 02/28/24 End: 02/15/28 Due: 02/15/29

Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04660097 Org: User:
Start: 05/20/21 End: 11/20/23 Due: 11/20/24

Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure

Phase: N/A Priority: Normal
NCT ID: NCT06786208 Org: User:
Start: 02/01/25 End: 06/30/27 Due: 06/30/28